Google, DeepMind

Google DeepMind CEO says 2025's the year we start popping pills AI helped invent
Nobel Prize winner Demis Hassabis thinks human trials will happen soon Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google DeepMind CEO Demis Hassabis suggested Tuesday.
Google-backed, AI-developed drugs are headed to trial by 2026, DeepMind CEO says
Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.
Trials of drugs developed with AI could begin this year, Google DeepMind CEO says
The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.
Europe accelerates AI drug discovery as DeepMind spinoff targets trials this year
Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. “We’ll hopefully have
DeepMind expects clinical trials for AI-designed drugs this year
Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive officer. “We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Google's DeepMind eyes clinical trials for AI-designed drugs in 2025 - report
Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis. "We'll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Roll over, Darwin: How Google DeepMind's 'mind evolution' could enhance AI thinking
This new approach, based on natural selection, dramatically improves the reliability of large language models for practical ...
Impressively Real AI Commercial Has No Actors, Locations Or Sets
A demo car ad created with Veo 2 from Google DeepMind is so realistic that it's hard to spot the amazing locations, ...
MIT Technology Review9h
The Download: OpenAI’s agent, and what to expect from robotics
This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of ...
Microsoft’s relationship with OpenAI cracked when it hired Mustafa Suleyman, rival Marc Benioff says
Salesforce CEO Marc Benioff said that the two AI leaders, Sam Altman and Mustafa Suleyman do not care for each other.
DeepMind’s new inference-time scaling technique improves planning accuracy in LLMs
With "Mind Evolution" LLMs can use search and genetic algorithms to generate and combine different solutions and find the optimal one.
A Chinese startup just showed every American tech company how quickly it's catching up in AI
The Chinese startup DeepSeek has released a new AI reasoning model that appears to rival the abilities of a frontier model ...
MIT Technology Review11h
OpenAI launches Operator—an agent that can use a computer for you
The announcement confirms one of two rumors that circled the internet this week. The other was about superintelligence.
Alphabet Has an Nvidia-Like Business. It Could Be Worth Hundreds of Billions.
Alphabet has an Nvidia-like business inside it. It could be the most valuable part of the internet search giant. Some investors might not know that Alphabet has an AI chip business among its many ...